Entrada Therapeutics Inc
NASDAQ:TRDA
P/S
Price to Sales
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
Market Cap | P/S | ||||
---|---|---|---|---|---|
US |
Entrada Therapeutics Inc
NASDAQ:TRDA
|
481.9m USD | 3 | ||
US |
Abbvie Inc
NYSE:ABBV
|
283.9B USD | 5.2 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
166.4B USD | 5.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.9B USD | 11 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.3B USD | 8.2 | ||
AU |
CSL Ltd
ASX:CSL
|
135.2B AUD | 6.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
44.9B USD | 8.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.3B USD | 3.3 | ||
KR |
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.